ARTICLE | Company News

Novo Nordisk sales and marketing update

August 3, 2015 7:00 AM UTC

The German Institute for Quality and Efficiency in Health Care (IQWiG) said in an early benefit assessment that “no hint of added benefit” can be derived for Tresiba insulin degludec to treat Type I or Type II diabetes in children and adolescents. The agency said Novo Nordisk only presented a study with Type I diabetics and the results showed no differences between treatment groups in mortality, symptoms and most side effects. In girls with Type I diabetes, serious adverse events occurred more frequently than in the comparator group, and the agency said there is a “hint of lesser benefit” vs. the appropriate comparator therapy for girls. ...